Growth factors in idiopathic pulmonary fibrosis: Relative roles

Respiratory Research

Volumn 3, Issue , 2001, Pages

  Allen, Jeremy T ^a   Spiteri, Monica A ^a  

^a KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Alveolar epithelial cell; Apoptosis; Growth factor; Idiopathic pulmonary fibrosis; Myofibroblast

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; CAPTOPRIL; CASPASE INHIBITOR; COLCHICINE; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; ENDOTHELIN 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL FUNCTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; EPITHELIUM CELL; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MODULATION; MYOFIBROBLAST; NONHUMAN; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

EID: 25444467151     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/rr162     Document Type: Review

References (55)

1. The American Thoracic Society and the European Respiratory Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161:646-664.
2. Flaherty KR, Toews GB, Lynch JP, Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ: Steroids in pulmonary fibrosis: A perspective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001, 110:278-282.
3. Collard HR, King TE Jr: Treatment of idiopathic pulmonary fibrosis: The rise and fall of corticosteroids. Am J Med 2001, 110:326-328.
4. Lasky JA, Brody AR: Interstitial fibrosis and growth factors. Environ Health Perspect 2000, 108:751-762.
5. Marshall RP, McAnulty RJ, Laurent GJ: The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Int J Biochem Cell Biol 1997, 29:107-120.
6. Blom IE, van Dijk AJ, de Weger RA, Tilanus MGJ, Goldschmeding R: Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. J Clin Pathol Mol Pathol 2001, 54:192-196.
7. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 2000, 162:755-758.
8. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV: Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 27:1014-1020.
9. Katzenstein ALA, Myers JL: Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
10. Selman M, King TE Jr, Pardo A: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001, 134:136-151.
11. Kasper M, Haroske G: Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996, 11:463-483.
12. Wallace WA, Howie SE: Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999, 187:475-480.
13. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y: Expression and localisation of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993, 143:651-655.
14. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G: Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995, 152:22163-22169.
15. Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159:1061-1069.
16. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S. Localisation of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995, 152:2084-2089.
17. Yoshida M, Sakuma J, Hayashi S, Kinya A, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, Kishimoto T: A histologially distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B gene. Proc Natl Acad Sci USA 1995, 92:9570-9574.
18. Gurujeyalakshmi G, Hollinger MA, Giri SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999, 276:L311-L318.
19. Khalil N, O'Connor RN, Unruh HW, Warren PW, Falnders KC, Kemp A, Bereznay OH, Greenberg AH: Increased production and immunohistochemical localisation of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991, 5:155-162.
20. Bloor CA, Knight RA, Kedia RK, Spiteri MA, Allen JT: Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 2001, 164:265-272.
21. Cambrey AD, Kwon OJ, Gray AJ, Harrison NK, Yacoub M, Barnes PJ, Laurent GJ, Chung KF: Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells. Clin Sci 1995, 89:611-617.
22. Allen JT, Bloor CA, Knight RA, Spiteri MA: Expression of insulin-like growth factor binding proteins in broncholaveolar lavage fluid of patients with pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1998, 19:250-258.
23. Chadelat K, Boule M, Corroyer S, Faroux B, Delaisi B, Tournier G, Clement A: Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. Eur Respir J 1998, 11: 1329-1336.
24. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A: Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta 2001, 1538:47-58.
25. Parker E, Bloor CA, Knight RA, Spiteri MA, Allen JT: Transforming growth factor-β-induced changes in insulin-like growth factor binding protein expression in lung fibroblasts [abstract]. Thorax 2000, 55:A15.
26. Wallace WA, Ramage EA, Lamb D, Howie SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995, 101:436-441.
27. Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ, Hutchinson IV: CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999, 60:343-346.
28. Fagan KA, McMurtry IF, Rodman DM: Role of endothelin-1 in lung disease. Respir Res 2001, 2:90-101.
29. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ, Giaid A: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997, 16:187-193.
30. Park S-H, Saleh D, Giaid A, Michel RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997, 156:600-608.
31. Brigstock DR: The connective tissue growth factor/cysteinerich 61/nephroblastoma overexpressed (CCN) family. Endocrine Rev 1999, 20:189-206.
32. Allen JT, Knight RA, Bloor CA, Spiteri MA: Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999, 21:693-700.
33. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H: A preliminary study of long term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
34. Gauldie J, Galt T, Anzano MA, Deng C, Roberts AB: SMAD3 KO mouse is resistant to gene based TGF-beta1 induced fibrosis: Lack of activation of CTGF [abstract]. Am J Respir Crit Care Med 2001, 164:A759.
35. Zhang H-Y, Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor β1. Am J Respir Cell Mol Biol 1999, 21:658-665.
36. Morishima Y, Nomura A, Uchida Y, Noguchi Y, Sakamoto T, Ishii Y, Goto Y, Masuyama K, Zhang MJ, Hirano K, Mochizuki M, Ohtsuka M, Sekizawa K: Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001, 24:1-11.
37. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A: Fibroblasts from idiopathic pulminary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001, 24:591-598.
38. 2 and to express cyclooxygenase-2. J Clin Invest 1995, 95:1861-1868.
39. 2 production in normal and fibrotic lung fibroblasts. Potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 2000, 22:628-634.
40. 2. Am J Physiol 1999, 277:1165-1171.
41. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A: Tumour necrosis factor-alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225.
42. Chapman HA: A Fas pathway to pulmonary fibrosis. J Clin Invest 1999, 104:1-2.
43. Yanagisawa K, Osada H, Masuda A, Kondo M, Saito T, Yatabe Y, Takagi K, Takahashi T, Takahashi T: Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 1998, 17:1743-1747.
44. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999, 104:13-19.
45. Aoshiba K, Yasui S, Tamaoki J, Nagai A: The Fas/Fas ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000, 162:695-700.
46. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD: Fas-induced apoptosis of alveolar epithelial cells requires ANGII generation and receptor interaction. Am J Physiol 1999, 277:L1245-L1250.
47. Carrillo G, Estrada A, Mejia M, Morales J, Suarez T, Gaxiola M, Williams J, Selman M: Inhaled beclomethasone and colchicine (IBC) versus inhaled beclomethasone, colchicine and captopril (IBCCAP) in patients with idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2000, 161:A528.
48. Yi ES, Salgado M, Williams S, Kim SJ, Masliah E, Yin S, Ulich TR: Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation 1998, 22:315-325.
49. Dohi M, Hasegawa T, Yamamoto K, Marshall BC: Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000, 162:2302-2307.
50. Kuwano K, Kunitake R, Maeyama T, Hagimoto N, Kawasaki M, Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N: Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol 2001, 280:L316-L325.
51. Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, Digiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159:1437-1443.
52. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM: IFN-γ-inducible protein 10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999, 163:5686-5692.
53. Fehrenbach H, Kasper M, Haase M, Schuh D, Muller M: Differential immunolocalisation of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat Rec 1999, 254:61-73.
54. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello L, King GL: Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 2000, 275:40725-40731.
55. Shimo T, Nakanishi T, Kimura Y, Nishida T, Ishizeli K, Matsumura T, Takigawa M: Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J Biochem 1998, 124:130-140.